ELDN · Eledon Pharmaceuticals, Inc.
$3.40
-0.17 (-4.76%)
At close · Jul 28
Market Cap
$275.56M
Shares
77.19M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.40
Open$3.54
Day$3.32–3.56
52W$1.35–4.60
Avg vol 30d1.6M
Short int5.5M · 7.2% float · 3.9d
Short vol49%
Last earningsNov 7, 2025
DataJan 2020–Jul 2026
Filing10-Q · May 13
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 13, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Sell
Momentum
Strong
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+18%
above
Price vs 50-day avg
−10%
below
RSI (14)
38
neutral
MACD trend
Negative
52-week position
63%
mid-range
Momentum
relative strength
1-month return
−10%
trailing
6-month return
+49%
trailing
YTD return
+125%
this year
Relative strength
+42%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $3 — 50d above 200d
Institutional flow
Accumulating
33 of 122 funds reported for Jun 30 · net +505.7K sh shares · +13 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
7.15% of float · ▼ -29.5% MoM · 3.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
122 holders — near 3-yr high, broad support
Squeeze score
54
elevated · 0–100
Fundamentals
EPS growth
+21%
Y/Y
Free cash flow
$-62.4M
Balance sheet
$22.8M
net cash
Quant / Vol
risk profile
Volatility
90%
annualized · 1-yr
Max drawdown
−68%
past year
ATR
7.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+18%
Bullish
Price vs 50-day avg
−10%
Bearish
RSI (14)
38
Neutral
MACD trend
Negative
Bearish
52-week position
63%
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $4 › 200d $3 — 50d above 200d
Institutional flow
Accumulating
33 of 122 funds reported for Jun 30 · net +505.7K sh shares · +13 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
7.15% of float · ▼ -29.5% MoM · 3.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
122 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $1
Now $3 · 63%
52-wk high $5
vs 200-day avg +18%
vs 50-day avg -10%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ELDN
this stock
Eledon Pharmaceuticals, Inc.
|
$275.56M | +125.2% | — | — | 7.2% |
|
ONC
BeOne Medicines Ltd.
|
$471.01B | +7.3% | +22179.2% | 958.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.57B | +8.2% | +46.2% | 28.4 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.95B | -9.8% | +20.8% | 16.3 | 3.3% |
|
ARGX
Argenx SE
|
$55.61B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ELDN | -11.9% | -10.1% | +49.1% | -13.7% | +125.2% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -10.9% | -10.0% | +41.7% | -12.9% | +116.5% |
Key facts
CIK
1404281
CUSIP
28617K101
13F (30d)
32 filings
32 filers
Visit website
Investor relations